Published in Cancer Weekly, January 2nd, 2007
"Protox made substantial progress during the third quarter with the acquisition of PRX321 from Neurocrine Biosciences and the U.S. Public Health Service," said Dr. Fahar Merchant, president and CEO of Protox. "PRX321 significantly expands our pipeline with a Phase II clinical program that utilizes our core expertise in toxin-based targeted therapies."
Merchant added: "Approval from Health Canada for our Clinical Trial Application, received subsequent to quarter's end, allows us to initiate a Phase I human clinical trial for PRX302 to treat adult...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.